Intellia Therapeutics is trading 5.09% up at $13.38 after closing at $12.73 on August 31, 2026, with no confirmed company-specific announcement, earnings release, or regulatory catalyst identified for the after-hours move.
- Recent coverage highlights earlier Phase III lonvo-z results and an 87% reduction in hereditary-angioedema attacks.
- The company has cash runway into 2028, but those developments were reported weeks earlier and do not clearly explain this evening’s gain.